ClinicalTrials.gg
CompletedNCT02546674NILOdeepRUpdated Jul 22, 2022Results posted

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline.

A Phase 4 interventional study of Nilotinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 70 sites in Germany. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2022-07-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
171
Allocation
Not applicable
Ages
18 Years to 120 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
15th of 66
171 · median 55
Started
2016
with 3 others
Phase 4
12 of 66
1 open now
Registered
57th of 66
by date
Lead sponsor
35 of 66
Novartis Pharmaceuticals

Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 15th largest by enrollment, is one of 4 that started in 2016, is one of 12 in phase 4, and was the 57th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 120 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

The main purpose of this study was to evaluate the rate of deep molecular response (MR4.5) after 24 months of therapy with nilotinib in newly diagnosed patients with chronic phase chronic myeloid leukemia (CML) using EUTOS (European Treatment and Outcome Study for CML)-standardized laboratories. All participants received nilotinib 300 mg twice daily (BID).

Read the detailed description

This was a Phase IV open-label, multi-center, single-arm study in participants with newly diagnosed Philadelphia chromosome positive (Ph+) CML in chronic phase for who nilotinib is the appropriate treatment at the discretion of the investigator.

A screening period of 2 weeks was used to assess eligibility and to taper participants off disallowed medications. Participants whose eligibility was confirmed entered a 24 months treatment phase with nilotinib 300mg BID. Nilotinib was prescribed by the investigator according to the individual needs of the participants.

03

Conditions studied

  • Chronic Myeloid Leukemia

Keywords

  • Chronic Myeloid Leukemia
  • Nilotinib
  • Molecular Response
  • MR4.5
04

Who can participate

Ages eligible
18 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with newly diagnosed (within 6 months) Philadelphia chromosome positive CML in chronic phase
  • Patients must be previously untreated for CML with the exception of 6 months treatment with hydroxyurea and a maximum of 6 weeks treatment with imatinib
  • Adequate end organ function
  • Normal serum levels ≥ lower limit of normal (LLN) of potassium, magnesium, total calcium corrected for serum albumin or phosphorus, or correctable to within normal limits with supplements, prior to the first dose of study medication.

Key Exclusion Criteria:

  • Known impaired cardiac function like long syndrome, history of myocardial infarction or unstable angina in the past 12 months.
  • Patients who are pregnant or breast feeding.

Other inclusion/exclusion criteria might apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
171 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Participants with newly diagnosed CML in chronic phase received nilotinib 300 mg BID for 24 months

    Drug: Nilotinib

Interventions

  • A daily dose of 300 mg was given to all participants as two 150 mg capsules BID. The prescription of study drug was not study dependent and followed medical needs of the participant only. The study treatment was administered for 24 months.

    Also known as: AMN107

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment

    Percentage of participants who were in deep molecular response MR4.5 (IS) at 24 months measured in a standardized EUTOS (European Treatment and Outcome Study for CML) MR4.5 laboratory. MR4.5 was defined as either (i) detectable disease ≤ 0.0032% BCR-ABL (fusion gene from breakpoint cluster region and Abelson genes) (IS) or (ii) undetectable disease in cDNA with 32000-99999 ABL1 transcripts or 77000-239999 glucuronidase beta (GUSB) transcripts. Responders: Participants with a MR4.5 at 24 months, or if the assessment at this time point was missing, with a MR4.5 at 21 months Non-responders: Participants dropping out early or not providing sufficient data for any other reason. Participants who achieved MR4.5 before 24 months, but was no longer in MR4.5 at 24 months or progressed (or was no longer in MR4.5 at 21 months if evaluation at 24 months was missing). Confidence intervals were calculated based on the Exact Clopper-Pearson method.

    Time frame: Month 24 and Month 21 (if assessment at Month 24 was missing)

Secondary outcomes

  1. Percentage of Participants With MR4 at 24 Months of Study Treatment.

    Percentage of participants with MR4 at 24 months of study treatment. MR4 (IS) is defined as either (i) detectable disease ≤0.01% BCR-ABL by IS or (ii) undetectable disease in cDNA with 10000 - 31999 ABL1 transcripts or 24000 - 76999 GUSB transcripts. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

    Time frame: Month 24

  2. Percentage of Participants With Major Molecular Response (MMR) at 12 Months of Study Treatment

    Percentage of participants with MMR at 12 months of study treatment. MMR is defined as ≤ 0.1% BCR-ABL by IS, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

    Time frame: Month 12

  3. Percentage of Participants With Complete Cytogenetic Response (CCyR) at 6 Months of Study Treatment

    Percentage of participants with CCyR at 6 months of study treatment. Cytogenetic response was assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow (a review of a minimum of 20 metaphases was required). CCyR was defined as a value of 0% Ph+ metaphases in bone marrow. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

    Time frame: Month 6

  4. Progression-free Survival

    Progression-free survival is defined as the time from the date of start of study treatment to the date of the first documented disease progression to accelerated phase (AP)/ blast crisis (BC) or death from any cause, whichever is earlier. AP is defined as: * 15% blasts in the peripheral blood or one marrow aspirate, but \<30% blasts in both the peripheral blood and bone marrow aspirate * 30% blasts plus promyelocytes in peripheral blood or bone marrow aspirate * 20% basophils in the peripheral blood or bone marrow Thrombocytopenia (\<100 x 109/Liter) that is unrelated to therapy Evidence of clonal evolution BC is defined as: ≥ 30% blasts in peripheral blood or bone marrow aspirate Appearance of extramedullary involvement other than hepatosplenomegaly proven by biopsy (i.e., chloroma)

    Time frame: From date of start of treatment to first documented disease progression to AP/ BC or death, assessed up to 24 months

  5. Time to Progression to AP/BC

    Time to progression to AP/BC is defined as the time from the date of start of study treatment to the date of earliest transformation to AP/BC, or CML-related death. AP is defined as: * 15% blasts in the peripheral blood or one marrow aspirate, but \<30% blasts in both the peripheral blood and bone marrow aspirate * 30% blasts plus promyelocytes in peripheral blood or bone marrow aspirate * 20% basophils in the peripheral blood or bone marrow Thrombocytopenia (\<100 x 109/L) that is unrelated to therapy Evidence of clonal evolution (with consensus of SC only) BC is defined as: ≥ 30% blasts in peripheral blood or bone marrow aspirate Appearance of extramedullary involvement other than hepatosplenomegaly proven by biopsy (i.e., chloroma)

    Time frame: From the date of start of study treatment to the date of earliest transformation to AP/BC or CML-related death, assessed up to 24 months

  6. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a GHS/QoL scale. The GHS/QoL scale has 7 possible scores of responses (1=very poor to 7=excellent). Scores were averaged and transformed to 0 to 100. Higher scores indicate better quality of life. A positive change from Baseline indicates improvement.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  7. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Physical Functioning

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the physical functioning scale, participants self-rated levels of difficulty in doing strenuous activities, taking a walk, how much they needed to stay in bed or a chair, or needed help with eating, dressing, bathing, using the toilet. The physical functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in physical functioning.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  8. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Role Functioning

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the role functioning scale, participants self-rated how much they were limited in doing work or daily activities, or in pursuing hobbies or other leisure time activities during the past week. The role functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in role functioning.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  9. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Emotional Functioning

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the emotional functioning scale, participants self-rated how much they felt tense, worried, irritable or depressed during the past week. The emotional functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in emotional functioning.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  10. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Cognitive Functioning

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the cognitive functioning scale, participants self-rated the extent of difficulty in concentrating on things or remembering things during the past week. The cognitive functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in cognitive functioning.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  11. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Social Functioning

    The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the social functioning scale, participants self-rated how much their physical condition or medical treatment interfered with their family life and social activities during the past week. The social functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in social functioning.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  12. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Symptom Burden

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in symptom burden domain indicates a worse outcome. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  13. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Worry/Mood

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each scale, scores were averaged and transformed to 0 to 100. A higher score in impact on worry/mood domain indicates a worse outcome. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  14. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Daily Life

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in impact on daily life domain indicates a worse outcome. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  15. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Care and Information

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with care and information domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  16. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Body Image Problems

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in body image problems domain indicates a worse outcome. A negative change from baseline indicates improvement.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

  17. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Social Life

    The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with social life domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.

    Time frame: Baseline, month 3, month 6, month 12, month 18 and month 24

07

Results

Posted Jul 22, 2022

Participant flow

The study was conducted across 73 centers in 1 country (Germany).

Participant flow — Overall Study
MilestoneNilotinib
Started171
Completed123
Not completed48
Withdrew: Adverse event19
Withdrew: Death1
Withdrew: Lost to follow-up1
Withdrew: Physician decision13
Withdrew: Pregnancy1
Withdrew: Progressive disease2
Withdrew: Protocol deviation2
Withdrew: Subject/guardian decision6
Withdrew: Withdrawal of informed consent3

Outcome measures

PrimaryPercentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment

Percentage of participants who were in deep molecular response MR4.5 (IS) at 24 months measured in a standardized EUTOS (European Treatment and Outcome Study for CML) MR4.5 laboratory. MR4.5 was defined as either (i) detectable disease ≤ 0.0032% BCR-ABL (fusion gene from breakpoint cluster region and Abelson genes) (IS) or (ii) undetectable disease in cDNA with 32000-99999 ABL1 transcripts or 77000-239999 glucuronidase beta (GUSB) transcripts. Responders: Participants with a MR4.5 at 24 months, or if the assessment at this time point was missing, with a MR4.5 at 21 months Non-responders: Participants dropping out early or not providing sufficient data for any other reason. Participants who achieved MR4.5 before 24 months, but was no longer in MR4.5 at 24 months or progressed (or was no longer in MR4.5 at 21 months if evaluation at 24 months was missing). Confidence intervals were calculated based on the Exact Clopper-Pearson method.

Time frame:
Month 24 and Month 21 (if assessment at Month 24 was missing)
Reported as:
Number · Percentage of participants
Percentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment
Percentage of participantsNilotinib
Percentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment35.3 (27.79 to 43.30)
SecondaryPercentage of Participants With MR4 at 24 Months of Study Treatment.

Percentage of participants with MR4 at 24 months of study treatment. MR4 (IS) is defined as either (i) detectable disease ≤0.01% BCR-ABL by IS or (ii) undetectable disease in cDNA with 10000 - 31999 ABL1 transcripts or 24000 - 76999 GUSB transcripts. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

Time frame:
Month 24
Reported as:
Number · Percentage of participants
Percentage of Participants With MR4 at 24 Months of Study Treatment.
Percentage of participantsNilotinib
Percentage of Participants With MR4 at 24 Months of Study Treatment.44.9 (36.91 to 53.03)
SecondaryPercentage of Participants With Major Molecular Response (MMR) at 12 Months of Study Treatment

Percentage of participants with MMR at 12 months of study treatment. MMR is defined as ≤ 0.1% BCR-ABL by IS, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

Time frame:
Month 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Major Molecular Response (MMR) at 12 Months of Study Treatment
Percentage of participantsNilotinib
Percentage of Participants With Major Molecular Response (MMR) at 12 Months of Study Treatment60.3 (52.12 to 67.99)
SecondaryPercentage of Participants With Complete Cytogenetic Response (CCyR) at 6 Months of Study Treatment

Percentage of participants with CCyR at 6 months of study treatment. Cytogenetic response was assessed as the percentage of Philadelphia positive (Ph+) metaphases in the bone marrow (a review of a minimum of 20 metaphases was required). CCyR was defined as a value of 0% Ph+ metaphases in bone marrow. Confidence intervals were calculated based on the Exact Clopper-Pearson method.

Time frame:
Month 6
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Cytogenetic Response (CCyR) at 6 Months of Study Treatment
Percentage of participantsNilotinib
Percentage of Participants With Complete Cytogenetic Response (CCyR) at 6 Months of Study Treatment89.5 (66.86 to 98.70)
SecondaryProgression-free Survival

Progression-free survival is defined as the time from the date of start of study treatment to the date of the first documented disease progression to accelerated phase (AP)/ blast crisis (BC) or death from any cause, whichever is earlier. AP is defined as: * 15% blasts in the peripheral blood or one marrow aspirate, but \<30% blasts in both the peripheral blood and bone marrow aspirate * 30% blasts plus promyelocytes in peripheral blood or bone marrow aspirate * 20% basophils in the peripheral blood or bone marrow Thrombocytopenia (\<100 x 109/Liter) that is unrelated to therapy Evidence of clonal evolution BC is defined as: ≥ 30% blasts in peripheral blood or bone marrow aspirate Appearance of extramedullary involvement other than hepatosplenomegaly proven by biopsy (i.e., chloroma)

Time frame:
From date of start of treatment to first documented disease progression to AP/ BC or death, assessed up to 24 months
Reported as:
Median · Months
Progression-free Survival
MonthsNilotinib
Progression-free SurvivalNA (NA to NA)
SecondaryTime to Progression to AP/BC

Time to progression to AP/BC is defined as the time from the date of start of study treatment to the date of earliest transformation to AP/BC, or CML-related death. AP is defined as: * 15% blasts in the peripheral blood or one marrow aspirate, but \<30% blasts in both the peripheral blood and bone marrow aspirate * 30% blasts plus promyelocytes in peripheral blood or bone marrow aspirate * 20% basophils in the peripheral blood or bone marrow Thrombocytopenia (\<100 x 109/L) that is unrelated to therapy Evidence of clonal evolution (with consensus of SC only) BC is defined as: ≥ 30% blasts in peripheral blood or bone marrow aspirate Appearance of extramedullary involvement other than hepatosplenomegaly proven by biopsy (i.e., chloroma)

Time frame:
From the date of start of study treatment to the date of earliest transformation to AP/BC or CML-related death, assessed up to 24 months
Reported as:
Median · Months
Time to Progression to AP/BC
MonthsNilotinib
Time to Progression to AP/BCNA (NA to NA)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a GHS/QoL scale. The GHS/QoL scale has 7 possible scores of responses (1=very poor to 7=excellent). Scores were averaged and transformed to 0 to 100. Higher scores indicate better quality of life. A positive change from Baseline indicates improvement.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Global Health Status (GHS)/Quality of Life (QoL)
Score on a scaleNilotinib
Month 35.1 ± 22.39
Month 66.3 ± 20.29
Month 126.0 ± 25.09
Month 184.0 ± 26.34
Month 242.4 ± 27.05
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Physical Functioning

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the physical functioning scale, participants self-rated levels of difficulty in doing strenuous activities, taking a walk, how much they needed to stay in bed or a chair, or needed help with eating, dressing, bathing, using the toilet. The physical functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in physical functioning.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Physical Functioning
Score on a scaleNilotinib
Month 30.2 ± 15.52
Month 60.7 ± 16.58
Month 12-1.4 ± 18.70
Month 18-0.7 ± 18.45
Month 24-3.2 ± 22.51
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Role Functioning

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the role functioning scale, participants self-rated how much they were limited in doing work or daily activities, or in pursuing hobbies or other leisure time activities during the past week. The role functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in role functioning.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Role Functioning
Score on a scaleNilotinib
Month 3-0.1 ± 33.22
Month 62.0 ± 29.19
Month 120.5 ± 32.11
Month 180.4 ± 34.57
Month 240.4 ± 35.41
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Emotional Functioning

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the emotional functioning scale, participants self-rated how much they felt tense, worried, irritable or depressed during the past week. The emotional functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in emotional functioning.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Emotional Functioning
Score on a scaleNilotinib
Month 38.1 ± 20.73
Month 68.6 ± 22.06
Month 127.2 ± 25.59
Month 184.7 ± 24.48
Month 240.0 ± 21.14
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Cognitive Functioning

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the cognitive functioning scale, participants self-rated the extent of difficulty in concentrating on things or remembering things during the past week. The cognitive functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in cognitive functioning.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Cognitive Functioning
Score on a scaleNilotinib
Month 3-2.3 ± 20.67
Month 6-3.8 ± 23.10
Month 12-7.1 ± 24.65
Month 18-8.0 ± 27.77
Month 24-8.3 ± 28.67
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Social Functioning

The EORTC QLQ-C30 is a patient completed 30 item questionnaire that is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, six single items and a global health status/QoL scale. For the social functioning scale, participants self-rated how much their physical condition or medical treatment interfered with their family life and social activities during the past week. The social functioning scale had 4 possible scores (1=not at all, 2=a little, 3=quite a bit, 4=very much). Scores were averaged and transformed to 0 to 100. Higher scores indicate better functioning. A positive change from baseline indicates improvement in social functioning.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30): Social Functioning
Score on a scaleNilotinib
Month 3-0.7 ± 26.83
Month 60.3 ± 26.03
Month 12-1.2 ± 27.95
Month 18-1.2 ± 28.15
Month 24-9.2 ± 28.13
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Symptom Burden

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in symptom burden domain indicates a worse outcome. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Symptom Burden
Score on a scaleNilotinib
Month 32.9 ± 13.90
Month 62.4 ± 13.76
Month 123.6 ± 14.29
Month 182.5 ± 12.85
Month 243.2 ± 14.46
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Worry/Mood

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each scale, scores were averaged and transformed to 0 to 100. A higher score in impact on worry/mood domain indicates a worse outcome. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Worry/Mood
Score on a scaleNilotinib
Month 3-3.4 ± 27.01
Month 6-4.7 ± 26.04
Month 12-6.0 ± 25.55
Month 18-3.8 ± 28.40
Month 24-2.0 ± 25.22
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Daily Life

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in impact on daily life domain indicates a worse outcome. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Impact on Daily Life
Score on a scaleNilotinib
Month 3-3.6 ± 25.59
Month 6-6.4 ± 24.07
Month 12-6.2 ± 26.50
Month 18-6.4 ± 27.87
Month 24-10.0 ± 31.61
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Care and Information

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with care and information domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Care and Information
Score on a scaleNilotinib
Month 34.3 ± 30.47
Month 65.6 ± 33.71
Month 12-0.6 ± 34.30
Month 182.2 ± 30.35
Month 2412.3 ± 30.35
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Body Image Problems

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in body image problems domain indicates a worse outcome. A negative change from baseline indicates improvement.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Body Image Problems
Score on a scaleNilotinib
Month 32.1 ± 32.72
Month 63.1 ± 28.92
Month 127.0 ± 28.40
Month 185.7 ± 31.33
Month 243.3 ± 35.71
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Social Life

The EORTC QLQ-CML 24 is an internationally developed disease specific health-related quality of life questionnaire for CML patients. The questionnaire is composed of four multi-item scales and two single-item scales. The module consists of 24 items assessing symptoms burden (13 items), impact on worry/mood (4 items), impact on daily life (3 items), satisfaction with care and information (2 items) body image problems (1 item) and satisfaction with social life (1 item). The items were measured on four levels: 1=not at all, 2=a little, 3=quite a bit, 4=very much. For each domain, scores were averaged and transformed to 0 to 100. A higher score in satisfaction with social life domain indicates a higher level of satisfaction. A positive change from baseline indicates increasing satisfaction.

Time frame:
Baseline, month 3, month 6, month 12, month 18 and month 24
Reported as:
Mean · Score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Chronic Myeloid Leukemia Specific 24 (EORTC QLQ-CML 24): Satisfaction With Social Life
Score on a scaleNilotinib
Month 33.9 ± 34.22
Month 69.7 ± 39.76
Month 126.6 ± 41.19
Month 188.5 ± 39.60
Month 2414.0 ± 30.05

Adverse events

Collected over Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of 25 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib1/171 (0.6%)38/171 (22.2%)148/171 (86.5%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventNilotinib
Peripheral arterial occlusive diseaseVascular disorders3/171
ThrombocytopeniaBlood and lymphatic system disorders2/171
Coronary artery diseaseCardiac disorders2/171
Abdominal painGastrointestinal disorders2/171
GastritisGastrointestinal disorders2/171
DepressionPsychiatric disorders2/171
AnaemiaBlood and lymphatic system disorders1/171
Blood loss anaemiaBlood and lymphatic system disorders1/171
LymphadenopathyBlood and lymphatic system disorders1/171
NeutropeniaBlood and lymphatic system disorders1/171
Most frequent other events
Showing 10 of 27
Most frequent other events
EventNilotinib
PruritusSkin and subcutaneous tissue disorders37/171
FatigueGeneral disorders34/171
NasopharyngitisInfections and infestations31/171
HeadacheNervous system disorders29/171
RashSkin and subcutaneous tissue disorders26/171
AlopeciaSkin and subcutaneous tissue disorders25/171
ArthralgiaMusculoskeletal and connective tissue disorders22/171
DiarrhoeaGastrointestinal disorders20/171
NauseaGastrointestinal disorders20/171
Back painMusculoskeletal and connective tissue disorders18/171

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Nilotinib
Mean55.2 ± 13.87
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female63
Male108
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nilotinib
Caucasian170
Asian1
08

Study locations

70 sites
  • Novartis Investigative Site
    Mannheim, Baden-Wuerttemberg 68305, Germany
  • Novartis Investigative Site
    Herne, Nordrhein-Westfalen 44625, Germany
  • Novartis Investigative Site
    Luebeck, Schleswig-holstein 23563, Germany
  • Novartis Investigative Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigative Site
    Augsburg, 86179, Germany
  • Novartis Investigative Site
    Bad Mergentheim, 97980, Germany
  • Novartis Investigative Site
    Bad Reichenhall, 83435, Germany
  • Novartis Investigative Site
    Bad Saarow, 15526, Germany
  • Novartis Investigative Site
    Bad Soden, 65812, Germany
  • Novartis Investigative Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Bayreuth, 95445, Germany
  • Novartis Investigative Site
    Berlin, 12351, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Berlin, 13357, Germany
  • Novartis Investigative Site
    Berlin, 13581, Germany
  • Novartis Investigative Site
    Berlin, 14195, Germany
  • Novartis Investigative Site
    Biberach, 88400, Germany
  • Novartis Investigative Site
    Bremerhaven, 27568, Germany
  • Novartis Investigative Site
    Chemnitz, 09113, Germany
  • Novartis Investigative Site
    Donauwoerth, 86609, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Duesseldorf, 40225, Germany
  • Novartis Investigative Site
    Duesseldorf, 40479, Germany
  • Novartis Investigative Site
    Erfurt, 99085, Germany
  • Novartis Investigative Site
    Essen, 45136, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Georgsmarienhuette, 49124, Germany
  • Novartis Investigative Site
    Giessen, 35392, Germany
  • Novartis Investigative Site
    Goslar, 38642, Germany
  • Novartis Investigative Site
    Göppingen, 73035, Germany
  • Novartis Investigative Site
    Halberstadt, 38820, Germany
  • Novartis Investigative Site
    Halle S, 06120, Germany
  • Novartis Investigative Site
    Halle, 06110, Germany
  • Novartis Investigative Site
    Hannover, 30161, Germany
  • Novartis Investigative Site
    Hannover, 30170, Germany
  • Novartis Investigative Site
    Heidelberg, 69115, Germany
  • Novartis Investigative Site
    Heidelberg, 69120, Germany
  • Novartis Investigative Site
    Jena, 07740, Germany
  • Novartis Investigative Site
    Kassel, 34125, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Koeln, 50671, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Magdeburg, 39104, Germany
  • Novartis Investigative Site
    Memmingen, 87700, Germany
  • Novartis Investigative Site
    Minden, 32429, Germany
  • Novartis Investigative Site
    Moers, 47441, Germany
  • Novartis Investigative Site
    Muelheim, 45468, Germany
  • Novartis Investigative Site
    Muenchen, 80335, Germany
  • Novartis Investigative Site
    Muenster, 48149, Germany
  • Novartis Investigative Site
    Mutlangen, 73557, Germany
  • Novartis Investigative Site
    Nuernberg, 90403, Germany
  • Novartis Investigative Site
    Nuernberg, 90419, Germany
  • Novartis Investigative Site
    Oldenburg, 26121, Germany
  • Novartis Investigative Site
    Paderborn, 33098, Germany
  • Novartis Investigative Site
    Passau, 94036, Germany
  • Novartis Investigative Site
    Potsdam, 14467, Germany
  • Novartis Investigative Site
    Rostock, 18059, Germany
  • Novartis Investigative Site
    Rotenburg, 27356, Germany
  • Novartis Investigative Site
    Saarbruecken, 66113, Germany
  • Novartis Investigative Site
    Schorndorf, 73614, Germany
  • Novartis Investigative Site
    Schweinfurt, 97422, Germany
  • Novartis Investigative Site
    Schwäbisch-Hall, 74523, Germany
  • Novartis Investigative Site
    Tübingen, 72076, Germany
  • Novartis Investigative Site
    Velbert, 42551, Germany
  • Novartis Investigative Site
    Westerstede, 26655, Germany
  • Novartis Investigative Site
    Wiesbaden, 65191, Germany
  • Novartis Investigative Site
    Wilhelmshaven, 26389, Germany
  • Novartis Investigative Site
    Wolfsburg, 38440, Germany
  • Novartis Investigative Site
    Worms, 67547, Germany
  • Novartis Investigative Site
    Wuerzburg, 97080, Germany
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2016 to primary completion in Feb 2021, 60 months.

Results were first posted in Jul 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2015
First posted
Sep 11, 2015
StartActual
Feb 18, 2016
Primary completionActual
Feb 23, 2021
CompletionActual
Mar 25, 2021
Results first posted
Jul 22, 2022
Last update
Jul 22, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02546674
Responsible party
Sponsor
First posted
Sep 11, 2015
Start date
Feb 18, 2016
Primary completion
Feb 23, 2021
Completion
Mar 25, 2021
Results posted
Jul 22, 2022
Last update
Jul 22, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion